Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RNS - Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer

Company: Compugen Ltd. Date: 2025-07-21 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.htm) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

   

�������'� ������ �� ����� ����� ������ ������ ��������� ������� �� COM701 ����� ����� ���� �������� false

|     |     |
| --- | --- |
| �������� ��"� | 2 380 |
| COMPUGEN LTD |
| Corporation no: 511779639 | 12833 |
| - - - |
|     |

|     |     |     |     |     |     |     |     |     |     |     |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|     | Israel Securities Authority |     |     | Tel Aviv Stock Exchange |     | C002 ( Public ) |     | Reported via MAGNA: | 21/07/2025 |     |
|     | www.isa.gov.il |     |     | www.tase.co.il |     |     |     | Reference: | 2025-02-054060 | Time of broadcast: 13:20 13:20 |

- - -

The corporation scheduled the publication of the report to 21/07/2025 14:00Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000  

  

|     |     |
| --- | --- |
|     | The corporation is a foreign private issuer as defined by U.S. Securities Laws. |

  

Attached hereto is a report on*�������'� ������ �� ����� ����� ������ ������ ��������� ������� �� COM701 ����� ����� ���� ��������*  

*a2533465\_isa.pdf*

|     |     |
| --- | --- |
|     |     |
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): |     |
|     |     |
|     |     |
| - - - |     |
| Stock Exchange/Market: TASE | Date of revision of form structure: 06/08/2024 |
| Address: Harokmim 26 , Holon 5885849   , Tel: 03-7658585 , 03-7658525 Fax: 03-7658555 |     |
| E-mail address: eranbd@cgen.com |     |
|     |     |
| Previous names of reporting entity: |     |
|     |     |
| Name of the Signatory: Ben Dor Eran Position of Signatory in the reporting corporation: General Counsel & Corporate Secretary Name of Employer Company: |     |
| Address: Harokmim 26 , Holon 5885849 Telephone: 03-7658585 Facsimile: 03-7658555 E-mail: eranbd@cgen.com 1 |     |
|     |